LEADERSHIP

We have assembled a team with extensive experience in drug discovery, clinical development and commercial who lead our company with passion and a drive to serve our patient communities.

Jeffrey Goldberg, M.B.A.

President and Chief Executive Officer

Jeff Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization. Prior to joining Aeglea, Jeff served as president and chief executive officer at Immunitas from 2019-2021. Under his leadership, Immunitas grew significantly, raised additional capital, and is now in the clinic with its first asset. Prior to Immunitas, Jeff served as the founding chief operating officer at Akcea. At Akcea, he was responsible for building functions and leading teams across all aspects of the business, eventually growing the team from two employees to over 250 in multiple geographies. He played a significant role in the company’s initial public offering and fundraising activities, business development and the global launch of two rare disease drugs. Earlier in his career, Jeff was the vice president of business operations at Proteostasis Therapeutics, a rare disease company and also held roles of increasing responsibility at Genzyme, where he led teams through product development and global launches across multiple therapeutic areas. Jeff has an M.B.A. and a M.S. in Chemical Engineering from the Massachusetts Institute of Technology, and a B.S. in Chemical Engineering from Cornell University.
Bio

Jonathan D. Alspaugh, M.B.A.

Chief Financial Officer

Jonathan Alspaugh has over a decade of experience advising healthcare companies on strategic and financial matters. Jonathan joined Aeglea from Evercore where he most recently served as a managing director in the firm’s corporate advisory business. At Evercore, Jonathan was involved in numerous strategic transactions including advising Bristol-Myers Squibb on its acquisition of Celgene, Akebia on its merger with Keryx, PTC Therapeutics on its acquisition of Emflaza, and dozens of successful equity financings to support the strategic growth of clients in the biopharma space. Prior to Evercore, Jonathan was a member of Barclays Capital’s global healthcare investment banking team. Previously, Jonathan served in the United States Marine Corps infantry. Jonathan received an S.M. from the Harvard-MIT Division of Health Sciences and Technology, an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management and a B.S.E. and an M.S.E. in Nuclear Engineering and Radiological Sciences from the University of Michigan.
Bio

Cortney Caudill, M.B.A.

Chief Product Officer

Cortney Caudill has over 25 years of experience in the biotechnology and healthcare industry including leadership roles in manufacturing, site build and startup, quality, and business development. Prior to joining Aeglea, she was the Head of Baxalta’s Global Drug Product External Manufacturing Network and she was located in Zurich, Switzerland with responsibility for over 20 commercial and pipeline products. Cortney started her career in the United States Air Force and has held various roles of increasing responsibility at Cambrex, Vaxgen, Genentech, and Vetter Pharma. She played a key role in start-up the manufacturing facility for Samsung Biologics in Korea while negotiating strategic deals that drove revenue and future expansions of the campus. Cortney holds a B.S. in Biology and a B.A. in Psychology from The University of Texas as well as an M.B.A from Fordham University.
Bio

Michael C. Hanley, M.B.A.

Chief Business Officer

Mike Hanley has nearly 25 years of experience in the biopharmaceutical and healthcare industries. Prior to joining Aeglea, he served as vice president and U.S. chief commercial officer of Esteve Pharmaceuticals, S.A., where he played a key role in identifying a new corporate strategic vision and leading the establishment of a new U.S affiliate. Previously, Mike served in various roles of increasing responsibility at Horizon Therapeutics PLC, a global biopharmaceutical company, where he had P&L responsibility for the company’s rare disease portfolio. Prior to Horizon, he served in various commercial leadership roles at the U.S. affiliate of H. Lundbeck A/S, a global pharmaceutical company, where he led the launch and life cycle strategy of a product for a rare and devastating form of epilepsy. Mike holds a B.B.A. in Marketing from the University of Notre Dame and an M.B.A. from the Kellogg School of Management at Northwestern University.
Bio

Jim Kastenmayer, Ph.D., J.D.

General Counsel

Jim joins Aeglea from Viela Bio, where, as general counsel, he provided strategic guidance and legal advice including advising the company in connection with the FDA approval and launch of Uplizna® as well as the company’s acquisition by Horizon Therapeutics. Prior to Viela Bio, he served in roles of increasing responsibility at AstraZeneca including global legal director, where he advised on commercialization and market access strategies, collaboration agreements and handled legal proceedings, as well as senior patent director, accountable for delivering global IP estates for small and large molecule therapies. Earlier in his career, Jim served as IP counsel at MedImmune, and as an Associate at an IP boutique firm. Jim earned a J.D. from Georgetown University Law Center, a Ph.D. in biochemistry and cell & molecular biology from Michigan State University and a B.A. in biology from the University of Virginia and is a registered patent attorney.
Bio

Linda Neuman, M.D., M.B.A.

Chief Medical Officer

Dr. Linda Neuman has over 20 years of experience developing therapeutics across multiple indications in the biopharmaceutical industry. Prior to joining Aeglea, Linda served as vice president, clinical development at Catalyst Biosciences where she led the clinical development of their late-stage development program for a novel hemophilia treatment. Before Catalyst, she served as the interim chief medical officer at Adverum Biotechnologies, where she directed the early phase development for three gene therapy programs, including two Investigational New Drug Applications (IND) in rare disease and ophthalmology indications. She previously worked at Sunesis Pharmaceuticals where she led the filing of an IND and initiated a Phase 1b/2 clinical study and Puma Biotechnology, Inc., where she contributed to the successful New Drug Application (NDA) and Market Authorization Application (MAA) for neratininb. Earlier in her career, Linda held roles of increasing responsibility at Onyx Pharmaceuticals, Covidien Pharmaceuticals, Millennium Pharmaceuticals, Inc., and Schering-Plough. She began her career as an internist and practiced medicine for 10 years prior to joining industry. Linda earned an M.D. from Southern Illinois University School of Medicine, a B.S. in biology from Southern Illinois University, and an M.B.A from Indiana Wesleyan University.
Bio

Tricia Sterling, M.B.A.

Vice President, Patient Affairs

Tricia Sterling has over 20 years of experience in the pharmaceutical and biotechnology space with the majority of her time working with patients and caregivers with rare diseases. Prior to joining Aeglea, Tricia was the head of Patient Services at Amicus Therapeutics where she was responsible for developing the company’s patient support program in preparation for the first US product launch. Prior to Amicus Therapeutics, Tricia spent several years at Retrophin, now Travere, where she led the both the Patient Services and Patient Advocacy Departments working with patients and caregivers with rare and ultra rare diseases. Earlier in her career she held roles at Shire HGT (now Takeda) and Biogen. Tricia received both her B.A. in Business Administration and Communications and her M.B.A. in Management from the University of St. Thomas in St. Paul, MN.
Bio

Russell J. Cox

Chief Executive Officer, Epirium Bio

Russell Cox is president, chief executive officer and a member of the board of directors of Epirium Bio. Russell also serves on the board of directors of Gossamer Bio. Previously, he served as chief executive officer and a member of the board of directors at Vital Therapies. He also formerly served as executive vice president and chief operating officer of Jazz Pharmaceuticals. As COO he held responsibility for the company’s Commercial, R&D, Manufacturing, International, and Global Molecule Leadership teams. He worked in a variety of escalating senior management roles from 2010 to 2018, including executive vice president and chief commercial officer from March 2012 to May 2014. From January 2009 to January 2010, he was senior vice president and chief commercial officer of Ipsen Group, and from 2007 until December 2008 he was vice president of marketing at Tercica, Inc., a biotechnology company acquired by Ipsen Group. From 2003 to 2007, he was with Scios, Inc. (acquired by Johnson & Johnson in 2003), where he served as vice president of marketing. Prior to 2003, Russell was with Genentech, Inc. for 12 years, where he was a product team leader responsible for the company’s growth hormone franchise and led numerous product launches as a group product manager. Russell received a B.S. in biomedical science from Texas A&M University.
Bio

Jeffrey Goldberg, M.B.A.

President and Chief Executive Officer

Jeff Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization. Prior to joining Aeglea, Jeff served as president and chief executive officer at Immunitas from 2019-2021. Under his leadership, Immunitas grew significantly, raised additional capital, and is now in the clinic with its first asset. Prior to Immunitas, Jeff served as the founding chief operating officer at Akcea. At Akcea, he was responsible for building functions and leading teams across all aspects of the business, eventually growing the team from two employees to over 250 in multiple geographies. He played a significant role in the company’s initial public offering and fundraising activities, business development and the global launch of two rare disease drugs. Earlier in his career, Jeff was the vice president of business operations at Proteostasis Therapeutics, a rare disease company and also held roles of increasing responsibility at Genzyme, where he led teams through product development and global launches across multiple therapeutic areas. Jeff has an M.B.A. and a M.S. in Chemical Engineering from the Massachusetts Institute of Technology, and a B.S. in Chemical Engineering from Cornell University.
Bio

V. Bryan Lawlis, Ph.D.

Independent Director

Dr. Bryan Lawlis has nearly 40 years of experience in the biotechnology industry, including extensive experience as a director and officer. He served as CEO of Itero BioPharmaceuticals, LLC from 2011 to 2017 and from 2007 to 2011 was co-founder and CEO of Itero BioPharmaceuticals, Inc. He was president and CEO of Aradigm Corporation from 2001 to 2006. From 1996 to 2001, Bryan co-founded Covance Biotechnology Services and held the positions of president, CEO and executive chairman. He worked at Genentech from 1981 to 1996 and rose to the position of vice president of process science. Bryan’s current board appointments include independent directorships at BioMarin Pharmaceutical, Geron Corporation, and Coherus Biosciences. He holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in biochemistry from Washington State University.
Bio

Alison Lawton

Former President and CEO of Kaleido Biosciences

Alison Lawton is an executive leader with more than 30 years of experience in biopharma and most recently served as president and CEO of Kaleido Biosciences. Prior to Kaleido Biosciences, she served as chief operating officer of Aura Biosciences and OvaScience and worked at various positions of increasing responsibility at Genzyme, and subsequently at Sanofi-Aventis, including as head of Genzyme Biosurgery and prior senior vice president of Global Market Access. Alison currently serves as independent director for X4 Pharmaceuticals and ProQR Therapeutics and has served on the boards of directors of Verastem, CoLucid until its acquisition by Eli Lilly, and Cubist Pharmaceuticals until its acquisition by Merck & Co. She is past president and chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for Cell and Gene Therapy Committee. She earned her BSc in Pharmacology, with honors, from King’s College London.
Bio

Ivana Magovčević-Liebisch, Ph.D., J.D.

President & Chief Executive Officer, Vigil Neuroscience

Dr. Ivana Magovčević-Liebisch has 20 years of senior management experience in biopharma with expertise in corporate development, M&A, IP and legal strategy, and pipeline and product portfolio development. She is currently the president and chief executive officer of Vigil Neuroscience. Prior to Vigil Neuroscience, she was executive vice president, chief business officer of Ipsen, a biopharmaceutical group focused on innovation and specialty care with medicines in oncology, neuroscience and rare diseases. Ivana previously served as the executive vice president, chief strategy and corporate development officer of Axcella Health Inc. From 2013 to 2017, she was senior vice president and head of global business development at Teva Pharmaceutical Industries, where she spearheaded multiple transactions ranging from licensing to acquisitions for the specialty drug business. From 2001 to 2013, she worked for Dyax Corp, rising to the positions of executive vice president and chief operating officer. During that time, she established the commercial infrastructure of the company’s first FDA-approved drug, Kalbitor®, for treatment of hereditary angioedema attacks. From 1998 to 2001, she was patent counsel and director of intellectual property at Transkaryotic Therapies. Ivana has a B.A. in biology and chemistry from Wheaton College, a Ph.D. in genetics from Harvard University Medical School and a J.D. in High Technology law from Suffolk University Law School.
Bio

Armen Shanafelt, Ph.D.

Independent Director

Dr. Armen Shanafelt was a general partner at Lilly Ventures, through 2020, where he led multiple investments (including company creation), serving as director on multiple private and public company boards. Prior to joining Lilly Ventures in 2009, he had over 20 years of experience in the pharmaceutical, biotechnology, and diagnostic industries. In addition to Aeglea, Armen serves as a director on the boards of Aileron Therapeutics (ALRN), Protagonist Therapeutics (PTGX), Sutro Biopharma, Surface Oncology. He is a Kauffman Fellow (class of 2014). Armen received his B.S. in chemistry and physics from Pacific Lutheran University and his Ph.D. in chemistry from the University of California, Berkeley.
Bio

Hunter C. Smith, M.B.A.

Chief Financial Officer, Rhythm Pharmaceuticals

Hunter Smith has served as the chief financial officer and treasurer of Rhythm Pharmaceuticals since 2017 and served as interim chief executive officer from March to July 2020. Prior to joining Rhythm, Hunter was vice president, finance and chief financial officer of Celgene Corporation’s inflammation and immunology business unit where he provided financial and strategic leadership for the global launch of Otezla®. Prior to Celgene, he held roles of increasing responsibility at Bunge Limited,a global food and agribusiness company, including director of investor relations, chief financial officer—Asia, corporate treasurer, and chief financial officer of Bunge's sugar and bioenergy segment. Hunter holds an M.B.A in finance from NYU’s Stern School of Business and a B.A. in history, with honors, from Northwestern University.
Bio

Marcio Souza, M.B.A.

President and Chief Executive Officer, Praxis Precision Medicines

Marcio Souza serves as the president & chief executive officer of Praxis Precision Medicines, Inc. Prior to joining Praxis Precision Medicines, Marcio served as chief operating officer at PTC Therapeutics, Inc. from May 2017 to April 2020 and its senior vice president and head of product strategy from July 2016 to May 2017. Marcio previously served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. He also served on the board of directors of Clearpoint Neuro, Inc. (previously MRI Interventions, Inc.). Marcio received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of São Paulo and an M.B.A. from Fundação Dom Cabral.
Bio

Open to Collaboration